DULERA®
(mometasone furoate and formoterol fumarate dihydrate 50 mcg/5 mcg, 100 mcg/5 mcg, 200 mcg/5 mcg) Inhalation Aerosol
(mometasone furoate and formoterol fumarate dihydrate 50 mcg/5 mcg, 100 mcg/5 mcg, 200 mcg/5 mcg) Inhalation Aerosol
Eligible health care professionals may request available samples, vouchers and/or coupons for DULERA for use with their appropriate patients.
DULERA is indicated for the twice-daily treatment of asthma in patients 5 years of age and older.
DULERA is NOT indicated for the relief of acute bronchospasm.
Use of long-acting beta2-adrenergic agonist (LABA) as monotherapy [without inhaled corticosteroid (ICS)] for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART) in PI section 5.1]. Available data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone.
Before prescribing DULERA, please read the accompanying Prescribing Information. The Patient Information also is available.